What Happened

ProQR reported positive Phase 1 data for AX-0810, its RNA editing oligonucleotide targeting NTCP. The drug showed dose-dependent modulation with up to 8-fold increases in total bile acids and an 8-week half-life in healthy volunteers.

Who Is Affected

Competitors in RNA therapeutics and cholestatic liver disease treatments should take note. The data specifically impacts companies working on biliary atresia and other bile acid-related disorders.

Market Impact

• PRQR stock dropped 21.55% despite positive data, continuing its pattern of negative reactions to clinical updates
• Trading volume spiked to 13.7x average with $41M market cap loss
• RNA/biotech peers showed mixed performance, indicating a stock-specific move

What to Watch

Monitor progression of next-gen candidate AX-0811 and development in biliary atresia. The 9 mg/kg cohort data remains pending, which could further validate the platform.